Advertisement
Advertisement
U.S. markets open in 5 hours 44 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Living Cell Technologies Limited (LCT.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
0.0080-0.0010 (-11.11%)
At close: 4:10PM AEDT
Advertisement

Living Cell Technologies Limited

330 Collins Street
Level 7
Melbourne, VIC 3000
Australia
61 3 8689 9997
http://www.lctglobal.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Bernard Tuch BSc, FRACP, GAICD, MBBS (Hons), Ph.D.Chairman & Interim CEO68.54kN/A1951
Mr. Daya UkaChief Financial Officer153.71kN/AN/A
Mr. Mark Andrew Licciardo B Bus (Acc), FCIS, FGIA, GAICD, GradDip CSPCompany Sec.N/AN/A1964
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was founded in 1987 and is based in Melbourne, Australia.

Corporate Governance

Living Cell Technologies Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement